Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research (Q26782621)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

0 references

0 references

Beatrice J Edwards

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Robert A Adler

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Ghada El-Hajj Fuleihan

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Douglas C Bauer

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Pauline M Camacho

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Bart L Clarke

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Gregory A Clines

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Juliet E Compston

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Matthew T Drake

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Murray J Favus

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Susan L Greenspan

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Ross McKinney

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Robert J Pignolo

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Deborah E Sellmeyer

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

0 references

publication date

1 January 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

31

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

16-35

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Safety issues with bisphosphonate therapy for osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

7 April 2017

Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Geographic and ethnic disparities in osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Atypical fracture of the femur in a patient using denosumab--a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Myocardial infarction risk among patients with fractures receiving bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Comparison between various fracture risk assessment tools

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw: a case report and narrative review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Antiresorptives and osteonecrosis of the jaw.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Bisphosphonates for osteoporosis--where do we go from here?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Analysis of the Comparative Effectiveness of 3 Oral Bisphosphonates in a Large Managed Care Organization: Adherence, Fracture Rates, and All-Cause Cost

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Bisphosphonates: The first 40years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 September 2017

Severely suppressed bone turnover and atypical skeletal fragility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

31 May 2018

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

31 May 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

31 May 2018

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Incidence of atypical nontraumatic diaphyseal fractures of the femur

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Fracture risk remains reduced one year after discontinuation of risedronate

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

The relationship between the chemistry and biological activity of the bisphosphonates.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Medication persistence with weekly versus daily doses of orally administered bisphosphonates

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Persistence with weekly alendronate therapy among postmenopausal women

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Does osteoporosis therapy invalidate FRAX for fracture prediction?

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Vitamin D insufficiency does not affect response of bone mineral density to alendronate

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: Mechanical analysis by the CT-based finite element method.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Atypical Femoral Fractures during Prolonged Use of Bisphosphonates: Short-Term Responses to Strontium Ranelate and Teriparatide

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Use of bisphosphonates and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Esophageal and gastric cancer incidence and mortality in alendronate users.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effect of osteoporosis treatment on mortality: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Osteoporosis medication and reduced mortality risk in elderly women and men.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Bisphosphonate Therapy, Death, and Cardiovascular Events Among Female Patients With CKD: A Retrospective Cohort Study

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Time since prior fracture is a risk modifier for 10-year osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Risk of new vertebral fracture in the year following a fracture

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Timing of subsequent fractures after an initial fracture

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Fracture risk and zoledronic acid therapy in men with osteoporosis

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

21 January 2018

Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Denosumab and atypical femoral fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906542

28 November 2018

Atypical femur fractures: 81 individual personal histories

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of postmenopausal women with osteoporosis with PTH(1–84) for 36 months: treatment extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral bisphosphonates are associated with reduced mortality after hip fracture

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A case of an unusual subtrochanteric fracture in a patient receiving denosumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical femoral fracture in a patient treated with denosumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of Atypical Femoral Fracture during and after Bisphosphonate Use

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Teriparatide Therapy for Osteonecrosis of the Jaw

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strontium ranelate related Stevens-Johnson syndrome: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/26350171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration

1 reference

https://api.crossref.org/works/10.1002/JBMR.2708

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/JBMR.2708

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26350171 AND SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26782621&oldid=1966101988"